+919405117673

Diabetology Medicine

Yurpeak KwikPen (Tirzepatide): Uses, Safety and Important Information

In stock

Description

Yurpeak KwikPen is a prescription-only injectable medicine containing tirzepatide. In India it is distributed and promoted by Cipla and manufactured by Eli Lilly, as a second brand of tirzepatide alongside Mounjaro.

Important: This page is general educational information. It is not medical advice and does not replace a consultation with a qualified doctor.

What is Yurpeak KwikPen?

Yurpeak contains tirzepatide, which activates two gut hormone receptors, GIP and GLP-1. It comes in a KwikPen, a multi-dose, single-patient-use pre-filled pen that is injected under the skin once a week. It is available in six strengths, from 2.5 mg to 15 mg. Only your prescriber decides which strength suits you and when it should change.

Product specifications

Brand name Yurpeak® KwikPen®

Active ingredient Tirzepatide

Drug class Dual GIP and GLP-1 receptor agonist

Form Solution for injection in a pre-filled pen

Device KwikPen: multi-dose, single-patient-use, with fixed doses

Doses per pen Four fixed once-weekly doses

Route Subcutaneous injection (under the skin)

Frequency Once weekly, as directed by your doctor

Storage Refrigerator, 2–8°C. Do not freeze

Marketed by Cipla Ltd (India)

Manufactured by Eli Lilly and Company

Legal status Prescription-only medicine

Available strengths

Yurpeak KwikPen is available in six strengths. Each strength is a separate pen, and the number shows the amount of tirzepatide delivered in each weekly dose.

2.5 mg

KwikPen

5 mg

KwikPen

7.5 mg

KwikPen

10 mg

KwikPen

12.5 mg

KwikPen

15 mg

KwikPen

A higher strength is not better for everyone. Your doctor chooses the strength and decides when to change it, based on your health, response and tolerance. Never switch pens or adjust your dose yourself.

What is it used for?

Yurpeak is intended for adults with type 2 diabetes, alongside a balanced diet and physical activity. It is also indicated for chronic weight management in adults with obesity (BMI of 30 or above), or overweight (BMI of 27 or above) with at least one weight-related health condition. It is not a cosmetic product, and it is not suitable for everyone. Results differ from person to person.

How does it work?

Tirzepatide mimics natural hormones released after eating. It helps the body release insulin when blood sugar is high, slows the emptying of the stomach and reduces appetite. Together, these effects can improve blood sugar control and support weight reduction.

Possible side effects

Common side effects include nausea, vomiting, diarrhoea, constipation, stomach pain and reduced appetite. They are often mild to moderate and tend to occur when treatment starts or the strength changes.

Seek urgent medical help for severe, persistent stomach pain, pain in the upper abdomen with fever or yellowing of the skin or eyes, signs of an allergic reaction, or symptoms of dehydration. The risk of low blood sugar is higher when Yurpeak is combined with insulin or sulfonylureas. This list is not complete, so read the patient leaflet that comes with your pen.

Talk to your doctor first if…

Tirzepatide caused thyroid C-cell tumours in animal studies. It should not be used by anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Tell your doctor if you have had pancreatitis, gallbladder, kidney or diabetic eye problems, or if you are pregnant, planning pregnancy or breastfeeding. Yurpeak may reduce the effectiveness of oral hormonal contraceptives, and because it delays stomach emptying, you should mention it before any surgery or anaesthesia.

Storage and handling

Store unused pens in a refrigerator at 2–8°C and do not freeze them. Never share a pen with another person, even if the needle is changed. Do not use a pen if the solution looks discoloured or contains particles, and follow the instructions in the leaflet.

Buy only genuine medicine

Counterfeit tirzepatide pens have been seized in India. Eli Lilly urges patients to buy only through authorised channels with a valid prescription. Be cautious of any website or seller offering Yurpeak without one.

Frequently asked questions

Is Yurpeak the same as Mounjaro?

Both contain tirzepatide. Yurpeak is the Cipla-distributed brand, and reports at launch said its price would match Mounjaro.

Can I get Yurpeak without a prescription?

No. It is a prescription-only medicine that needs medical supervision.

How soon will I see results?

This varies widely. Your doctor will review your progress and any side effects at follow-up visits.

Sources: Cipla press release, 10 December 2025; Business Standard on counterfeit seizures; the approved Yurpeak patient information leaflet.

Yurpeak® and KwikPen® are trademarks of their respective owners. This page is independent and does not sell medicines. If you experience a medical emergency, contact your doctor or local emergency services immediately.

Keywords